Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary. (2024). SKIN The Journal of Cutaneous Medicine, 8(2), s358. https://doi.org/10.25251/skin.8.supp.358